See All Slides - tctmd.com

Slides

Presentation TCT 2023

TCT 890: An Anomalous Intervention: High Risk Percutaneous Coronary Intervention in a Patient with Single Coronary Ostia with Reduced Left Ventricular Function

Presenter: Nathan Bugs

October 24, 2023

Presentation TCT 2023

TCT 811: Drug Eluting Balloon for Early Aggressive Neointimal Hyperplasia for Coronary Artery In-Stent Restenosis

Presenter: Parth Parikh

October 24, 2023

Presentation TCT 2023

Are Outcome Trials Necessary for Renal Denervation Therapies?

Presenter: Ajay Kirtane

October 24, 2023

Presentation TCT 2023

What Is a Vulnerable Plaque? Lessons From Intravascular Imaging

Presenter: Gary Mintz

October 24, 2023

Presentation TCT 2023

Index SAVR in Young Patients With Bicuspid AS Is Better for Lifetime Management

Presenter: Basel Ramlawi

October 24, 2023

Presentation TCT 2023

LVOT Obstruction Prevention and Management

Presenter: Robert Lederman

October 24, 2023

Presentation TCT 2023

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

Presenter: Martin Leon

October 24, 2023

Presentation TCT 2023

What Will the Next Trial Designs Look Like for Renal Denervation?

Presenter: Eric Secemsky

October 24, 2023

Presentation TCT 2023

Index TAVR in Young Patients With Bicuspid AS is Better for Lifetime Management

Presenter: Amit Vora

October 24, 2023

Presentation TCT 2023

Assessing the Risk of LV Failure After TAVR

Presenter: Sabah Skaf

October 24, 2023

Advertisement

Slides

TCT 890: An Anomalous Intervention: High Risk Percutaneous Coronary Intervention in a Patient with Single Coronary Ostia with Reduced Left Ventricular Function

TCT 811: Drug Eluting Balloon for Early Aggressive Neointimal Hyperplasia for Coronary Artery In-Stent Restenosis

Are Outcome Trials Necessary for Renal Denervation Therapies?

What Is a Vulnerable Plaque? Lessons From Intravascular Imaging

Index SAVR in Young Patients With Bicuspid AS Is Better for Lifetime Management

LVOT Obstruction Prevention and Management

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

What Will the Next Trial Designs Look Like for Renal Denervation?

Index TAVR in Young Patients With Bicuspid AS is Better for Lifetime Management

Assessing the Risk of LV Failure After TAVR

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content